These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 29112517)
21. [Predictors of long-term institutionalization in patients with Alzheimer's disease: role of caregiver burden]. Hirono N; Tsukamoto N; Inoue M; Moriwaki Y; Mori E No To Shinkei; 2002 Sep; 54(9):812-8. PubMed ID: 12428367 [TBL] [Abstract][Full Text] [Related]
22. Progression of Alzheimer's disease during a three-year follow-up using the CERAD-NB total score: Kuopio ALSOVA study. Hallikainen I; Hänninen T; Fraunberg M; Hongisto K; Välimäki T; Hiltunen A; Karppi P; Sivenius J; Soininen H; Koivisto AM; Int Psychogeriatr; 2013 Aug; 25(8):1335-44. PubMed ID: 23676340 [TBL] [Abstract][Full Text] [Related]
23. The effects of combine treatment of memantine and donepezil on Alzheimer's disease patients and its relationship with cerebral blood flow in the prefrontal area. Araki T; Wake R; Miyaoka T; Kawakami K; Nagahama M; Furuya M; Limoa E; Liaury K; Hashioka S; Murotani K; Horiguchi J Int J Geriatr Psychiatry; 2014 Sep; 29(9):881-9. PubMed ID: 24436135 [TBL] [Abstract][Full Text] [Related]
24. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential. Abushakra S; Porsteinsson A; Scheltens P; Sadowsky C; Vellas B; Cummings J; Gauthier S; Hey JA; Power A; Wang P; Shen L; Tolar M J Prev Alzheimers Dis; 2017; 4(3):149-156. PubMed ID: 29182706 [TBL] [Abstract][Full Text] [Related]
25. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy. Modrego PJ; Pina MA; Fayed N; Díaz M CNS Drugs; 2006; 20(10):867-77. PubMed ID: 16999455 [TBL] [Abstract][Full Text] [Related]
26. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease. Wilkinson D; Andersen HF Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761 [TBL] [Abstract][Full Text] [Related]
27. Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy. Wattmo C; Minthon L; Wallin ÅK Alzheimers Res Ther; 2016 Feb; 8():7. PubMed ID: 26883213 [TBL] [Abstract][Full Text] [Related]
29. Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Doody R; Wirth Y; Schmitt F; Möbius HJ Dement Geriatr Cogn Disord; 2004; 18(2):227-32. PubMed ID: 15256834 [TBL] [Abstract][Full Text] [Related]
30. Memantine (Ebixa) in clinical practice - results of an observational study. Calabrese P; Essner U; Forstl H Dement Geriatr Cogn Disord; 2007; 24(2):111-7. PubMed ID: 17622714 [TBL] [Abstract][Full Text] [Related]
31. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Mecocci P; Bladström A; Stender K Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640 [TBL] [Abstract][Full Text] [Related]
32. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies. Tariot PN J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847 [TBL] [Abstract][Full Text] [Related]
33. Solitary living in Alzheimer's disease over 3 years: association between cognitive and functional impairment and community-based services. Wattmo C; Londos E; Minthon L Clin Interv Aging; 2014; 9():1951-62. PubMed ID: 25484578 [TBL] [Abstract][Full Text] [Related]
34. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD). Ballard C; Thomas A; Gerry S; Yu LM; Aarsland D; Merritt C; Corbett A; Davison C; Sharma N; Khan Z; Creese B; Loughlin P; Bannister C; Burns A; Win SN; Walker Z; J Am Med Dir Assoc; 2015 Apr; 16(4):316-22. PubMed ID: 25523285 [TBL] [Abstract][Full Text] [Related]
35. Use of psychotropic medications in relation to neuropsychiatric symptoms, cognition and functional performance in Alzheimer's disease over a three-year period: Kuopio ALSOVA study. Törmälehto S; Martikainen J; Bell JS; Hallikainen I; Koivisto AM Int Psychogeriatr; 2017 Oct; 29(10):1723-1733. PubMed ID: 28625207 [TBL] [Abstract][Full Text] [Related]
36. Antidementia drug prescription sources and patterns after the diagnosis of dementia in Germany: results of a claims data-based 1-year follow-up. van den Bussche H; Kaduszkiewicz H; Koller D; Eisele M; Steinmann S; Glaeske G; Wiese B Int Clin Psychopharmacol; 2011 Jul; 26(4):225-31. PubMed ID: 21394033 [TBL] [Abstract][Full Text] [Related]
37. Cost and care of patients with Alzheimer's disease: clinical predictors in German health care settings. Reese JP; Hessmann P; Seeberg G; Henkel D; Hirzmann P; Rieke J; Baum E; Dannhoff F; Müller MJ; Jessen F; Geldsetzer MB; Dodel R J Alzheimers Dis; 2011; 27(4):723-36. PubMed ID: 21876256 [TBL] [Abstract][Full Text] [Related]